Interleukin-19 is a negative regulator of innate immunity and critical for colonic protection

Journal of Pharmacological Sciences

Volumn 115, Issue 2, 2011, Pages 105-111

  Azuma, Yasu Taka ^a   Matsuo, Yukiko ^a   Nakajima, Hidemitsu ^a   Yancopoulos, George D ^b   Valenzuela, David M ^b   Murphy, Andrew J ^b   Karow, Margaret ^b   Takeuchi, Tadayoshi ^a  

^a Osaka Prefecture University   (Japan)

^b REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Colonic inflammation; Cytokine; Inflammatory bowel disease (IBD); Interleukin 19; Macrophages

Indexed keywords

ENDOTOXIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 19; INTERLEUKIN 2; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; RECOMBINANT INTERLEUKIN 19; RECOMBINANT PROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; COLITIS; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; ENTERITIS; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOREGULATION; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; TH2 CELL; ULCERATIVE COLITIS; UPREGULATION;

EID: 79952321372     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10R02CR     Document Type: Review

References (50)

1. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307:1920-1925. (Pubitemid 40404695)
2. Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev. 2005;206:260-276. (Pubitemid 41105175)
3. Braat H, Peppelenbosch MP, Hommes DW. Interleukin-10-based therapy for inflammatory bowel disease. Expert Opin Biol Ther. 2003;3:725-731. (Pubitemid 36934972)
4. Li MC, He SH. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol. 2004;10: 620-625.
5. Yamamoto-Furusho JK. Innovative therapeutics for inflammatory bowel disease. World J Gastroenterol. 2007;13:1893-1896. (Pubitemid 46746374)
6. Wirtz S, Neurath MF. Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease. Int J Colorectal Dis. 2000;15: 144-160.
7. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol. 1999;11:648-656.
8. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 1993;75:253-261. (Pubitemid 23320289)
9. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993; 75:263-274. (Pubitemid 23320290)
10. Neurath ME, Fuss I, Kelsall BL, Stüber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182:1281-1290.
11. Boirivant M, Fuss IJ, Chu A, Strober W. Oxazolone colitis: A murine model of T Helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med. 1998;188:1929-1939. (Pubitemid 28536780)
12. Bailón E, Román J, Ramis I, Michelena P, Balsa D, Merlos M, et al. The new salicylate derivative UR-1505 modulates the Th2/humoral response in a dextran sodium sulphate model of colitis that resembles ulcerative colitis. J Pharmacol Sci. 2009;109:315-318.
13. Murakami I, Hamada Y, Yamane S, Fujino H, Horie S, Murayama T. Nicotine-induced neurogenic relaxation in the mouse colon: changes with dextran sodium sulfate-induced colitis. J Pharmacol Sci. 2009;109:128-138.
14. - cell-transferred SCID mice for preclinical evaluation of drugs for inflammatory bowel disease. J Pharmacol Sci. 2009;110:169-181.
15. Brandtzaeg P, Haraldsen G, Rugtveit J. Immunopathology of human inflammatory bowel disease. Springer Semin Immunopathol. 1997;18:555-589. (Pubitemid 27421337)
16. Gallagher G, Dickensheets H, Eskdale J, Izotova LS, Mirochnitchenko OV, Peat JD, et al. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun. 2000;1: 442-450.
17. Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC. STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol. 2001;167:3545-3549. (Pubitemid 32910793)
18. Pletnev S, Magracheva E, Kozlov S, Tobin G, Kotenko SV, Wlodawer A, et al. Characterization of the recombinant extracellular domains of human interleukin-20 receptors and their complexes with interleukin-19 and interleukin-20. Biochemistry. 2003;42:12617-12624. (Pubitemid 37337552)
19. Parrish-Novak J, Xu W, Brender T, Yao L, Jones C, West J, et al. Interleukins 19, 20, and 24 signal through two distinct receptor complexes - Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem. 2002;277:47517-47523. (Pubitemid 36159270)
20. Oral HB, Kotenko SV, Yilmaz M, Mani O, Zumkehr J, Blaser K, et al. Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 and IL-26. Eur J Immunol. 2006;36:380-388. (Pubitemid 43257461)
21. Liao SC, Cheng YC, Wang YC, Wang CW, Yang SM, Yu CK, et al. IL-19 induced Th2 cytokines and was up-regulated in asthma patients. J Immunol. 2004;173:6712-6718.
22. Zhong H, Wu Y, Belardinelli L, Zeng D. A2B adenosine receptors induce IL-19 from bronchial epithelial cells, resulting in TNF-alpha increase. Am J Respir Cell Mol Biol. 2006;35:587-592. (Pubitemid 44706432)
23. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nature Med. 2003;9:40-46. (Pubitemid 36098258)
24. Rømer J, Hasselager E, Nørby PL, Steiniche T, Thorn Clausen J, Kragballe K. Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J Invest Dermatol. 2003;121: 1306-1311. (Pubitemid 38005477)
25. Kõks S, Kingo K, Rätsep R, Karelson M, Silm H, Vasar E. Combined haplotype analysis of the interleukin-19 and -20 genes: relationship to plaque-type psoriasis. Genes Immun. 2004;5:662-667. (Pubitemid 40045304)
26. Wei CC, Chen WY, Wang YC, Chen PJ, Lee JY, Wong TW, et al. Detection of IL-20 and its receptors on psoriatic skin. Clin Immunol. 2005;117:65-72. (Pubitemid 41725471)
27. Li HH, Lin YC, Chen PJ, Hsiao CH, Lee JY, Chen WC, et al. Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis. Br J Dermatol. 2005;153:591-595. (Pubitemid 41248218)
28. Otkjaer K, Kragballe K, Funding AT, Clausen JT, Noerby PL, Steiniche T, et al. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br J Dermatol. 2005;153:911-918. (Pubitemid 41540754)
29. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203:2577-2587. (Pubitemid 44833335)
30. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 2007;178: 2229-2240. (Pubitemid 46233421)
31. Wolk K, Kunz S, Asadullah K, Sabat R. Immune cells as sources and targets of the IL-10 family members? J Immunol. 2002;168: 5397-5402.
32. Nagalakshmi ML, Murphy E, McClanahan T, de Waal Malefyt R. Expression patterns of IL-10 ligand and receptor gene families provide leads for biological characterization. Int Immunopharmacol. 2004;4:577-592. (Pubitemid 38553881)
33. Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol. 2002;169:4288-4297.
34. Jordan WJ, Eskdale J, Boniotto M, Lennon GP, Peat J, Campbell JD, et al. Human IL-19 regulates immunity through auto-induction of IL-19 and production of IL-10. Eur J Immunol. 2005;35: 1576-1582. (Pubitemid 40691438)
35. Valenzuela DM, Murphy AJ, Frendewey D, Gale NW, Economides AN, Auerbach W, et al. High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nature Biotechnol. 2003;21:652-659. (Pubitemid 36638092)
36. Tsuji F, Murai M, Oki K, Inoue H, Sasano M, Tanaka H, et al. Effects of SA13353, a transient receptor potential vanilloid 1 agonist, on leukocyte infiltration in lipopolysaccharide-induced acute lung injury and ovalbumin-induced allergic airway inflammation. J Pharmacol Sci. 2010;112:487-490.
37. Azuma YT, Matsuo Y, Kuwamura M, Yancopoulos GD, Valenzuela DM, Murphy AJ, et al. Interleukin-19 protects mice from innate-mediated colonic inflammation. Inflamm Bowel Dis. 2010;16:1017-1028.
38. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett. 2003;85:85-95. (Pubitemid 36071561)
39. Akira S, Takeda K. Toll-like receptor signalling. Nature Rev Immunol. 2004;4:499-511. (Pubitemid 38931765)
40. Henricson BE, Benjamin WR, Vogel SN. Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect Immun. 1990;58:2429-2437. (Pubitemid 20228221)
41. Ziegler-Heitbrock HW. Molecular mechanism in tolerance to lipopolysaccharide. J Inflamm. 1995;45:13-26.
42. Nomura F, Akashi S, Sakao Y, Sato S, Kawai T, Matsumoto M, et al. Endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol. 2000;164:3476-3479. (Pubitemid 30169796)
43. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell. 2002;110:191-202. (Pubitemid 34876547)
44. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17:1-14.
45. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376. (Pubitemid 37174535)
46. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim SO, et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signaling. Nature. 2003;424:743-748. (Pubitemid 37021696)
47. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765. (Pubitemid 32368050)
48. Shinkai K, Mohrs M, Locksley RM. Helper T cells regulate type-2 innate immunity in vivo. Nature. 2002;420:825-829. (Pubitemid 36019631)
49. Mahler M, Leiter EH. Genetic and environmental context determines the course of colitis developing in IL-10-deficient mice. Inflamm Bowel Dis. 2002;8:347-355.
50. Berg DJ, Kühn R, Rajewsky K, Müller W, Menon S, Davidson N, et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest. 1995;96: 2339-2347.